Ethnic variation in levels of circulating IgG autoantibodies to oxidised low-density lipoprotein

Atherosclerosis

Volumn 203, Issue 1, 2009, Pages 126-136

  Miller, Michelle A ^a   Strazzullo, Pasquale ^b   Karanam, Sharada ^a   Cappuccio, Francesco P ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atherosclerosis; Autoantibodies to oxidised LDL; Cardiovascular disease; Cell adhesion molecules; Coronary disease; Ethnicity

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AFRICAN AMERICAN; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID OXIDATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; CORONARY DISEASE; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; SMOKING;

EID: 60949111209     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.05.053     Document Type: Article

References (44)

1. Keidar S., Kaplan M., Shapira C., Brook J.G., and Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 103 (1994) 213-219
2. Mertens A., and Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 15 (2001) 2073-2084
3. Leslie D., Lipsky P., and Notkins A.L. Autoantibodies as predictors of disease. J Clin Invest 108 10 (2001) 1417-1422
4. Salonen J.T., Yla-Herttuala S., Yamamoto R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 8798 (1992) 883-887
5. Faviou E., Vourli G., Nounopoulos C., Zachari A., and Dionyssiou-Asteriou A. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease. Free Radic Res 39 4 (2005) 419-429
6. Palinski W., Rosenfeld M.E., Yla-Herttuala S., et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 86 4 (1989) 1372-1376
7. Hulthe J., Bokemark L., and Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21 1 (2001) 101-107
8. Paiker J.E., Raal F.J., and von Arb M. Auto-antibodies against oxidized LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann Clin Biochem 37 Pt 2 (2000) 174-178
9. Wu R., de Faire U., Lemne C., Witztum J.L., and Frostegard J. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 33 1 (1999) 53-59
10. Hulthe J. Antibodies to oxidized LDL in atherosclerosis development-clinical and animal studies. Clin Chim Acta 348 (2004) 1-8
11. Virella G., and Lopes-Virella M.F. Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol 10 (2003) 499-505
12. Suzuki K., et al., Japan Collaborative Cohort Study Group. The relationship between smoking habits and serum levels of 8-OHdG, oxidized LDL antibodies, Mn-SOD and carotenoids in rural Japanese residents. J Epidemiol 13 1 (2003) 29-37
13. Brizzi P., Tonolo G., Bertrand G., et al. Autoantibodies against oxidized low-density lipoprotein (ox-LDL) and LDL oxidation status. Clin Chem Lab Med 42 2 (2004) 164-170
14. Bilgen D., Sonmez H., Ekmekci H., et al. The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease. Clin Biochem 38 1 (2005) 92-96
15. Karolkiewicz J., Pilaczynska-Szczesniak L., Maciaszek J., and Osinski W. Insulin resistance, oxidative stress markers and the blood antioxidant system in overweight elderly men. Aging Male 9 3 (2006) 159-163
16. Doo Y.C., Han S.J., Lee J.H., et al. Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris. Am J Cardiol 93 (2004) 554-558
17. Tsimikas S., Brilakis E.S., Lennon R.J., et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 48 (2007) 425-433
18. Shoji T., Nishizawa Y., Fukumoto M., et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 148 1 (2000) 171-177
19. Balarajan R. Ethnic differences in mortality from ischaemic heart disease and cerebrovascular disease in England and Wales. Br Med J 302 (1991) 560-564
20. Cappuccio F.P. Ethnicity and cardiovascular risk: variations in people of African ancestry and South Asian origin. J Hum Hypertens 11 (1997) 571-576
21. Chia M.C. The role of adhesion molecules in atherosclerosis. Crit Rev Clin Lab Sci 35 (1998) 573-602
22. Weber C., Erl W., Weber K.S., and Weber P.C. Effects of oxidized low density lipoprotein, lipid mediators and statins on vascular cell interactions. Clin Chem Lab Med 37 (1999) 243-251
23. Frostegard J., Wu R., Haegerstrand A., et al. Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis 103 (1993) 213-219
24. Miller M.A., Sagnella G.A., Kerry S.M., et al. Ethnic differences in circulating soluble adhesion molecules: the Wandsworth heart and stroke study. Clin Sci 104 (2003) 591-598
25. Cappuccio F.P., Cook D.G., Atkinson R.W., and Wicks P.D. The Wandsworth Heart and Stroke Study. A population-based survey of cardiovascular risk factors in different ethnic groups. Methods and baseline findings. Nutr Metab Cardiovasc Dis 8 (1998) 371-378
26. Cappuccio F.P., Oakeshott P., Strazzullo P., and Kerry S.M. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross-sectional population-based study. BMJ 325 (2002 November 30) 1271-1274
27. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 84 (2004) 1381-1478
28. Festa A., Kopp H.P., Schernthaner G., and Menzel E.J. Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 41 (1998) 350-356
29. Lupattelli G., Marchesi S., Lombardini R., et al. Mechanisms of high-density lipoprotein cholesterol effects on the endothelial function in hyperlipemia. Metabolism 52 (2003) 1191-1195
30. Hulthe J., Wikstrand J., Lidell A., et al. Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 18 8 (1998) 1203-1211
31. George J., Harats D., Bakshi E., et al. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 68 2-3 (1999) 263-266
32. Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low-density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103 15 (2001) 1955-1960
33. Bergmark C., Wu R., de Faire U., Lefvert A.K., and Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 15 4 (1995) 441-445
34. Maggi E., Chiesa R., Melissano G., et al. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 14 (1994) 1892-1899
35. Maggi E., Marchesi E., Ravetta V., et al. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. J Hypertens 13 1 (1995) 129-138
36. Van de Vijver L.P., Steyger R., van Poppel G., et al. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 122 2 (1996) 245-253
37. Fialova L., Mikulikova L., Malbohan I., et al. Antibodies against oxidized low-density lipoproteins in pregnant women. Physiol Res 51 4 (2002) 355-361
38. Su J., Georgiades A., Wu R., et al. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188 1 (2006) 160-166 [Epub 2005, November 22]
39. Karvonen J., Paivansalo M., Kesaniemi Y.A., and Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108 17 (2003) 2107-2112
40. George J., Wexler D., Roth A., et al. Usefulness of anti-oxidized LDL antibody determination for assessment of clinical control in patients with heart failure. Eur J Heart Fail 8 1 (2006) 58-62
41. Fagerberg B., Bokemark L., and Hulthe J. The metabolic syndrome, smoking, and antibodies to oxidized LDL in 58-year-old clinically healthy men. Nutr Metab Cardiovasc Dis 11 4 (2001) 227-235
42. Wilson P.W., Ben-Yehuda O., McNamara J., et al. Autoantibodies to oxidized LDL and cardiovascular risk: the Framingham offspring study. Atherosclerosis 189 2 (2006) 364-368
43. Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun Rev 1 (2002) 233-237
44. Brizzi P., Isaja T., D'Agata A., et al. Oxidized LDL antibodies (OLAB) in patients with beta-thalassemia major. J Atheroscler Thromb 9 (2002) 139-144